Hanmi Pharm. Co., Ltd.

KSE 128940.KS

Hanmi Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 55.62%

Hanmi Pharm. Co., Ltd. Gross Profit Margin is 55.62% for the year ending December 31, 2023, a 3.07% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Hanmi Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 53.96%, a 2.61% change year over year.
Hanmi Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 52.59%, a -2.60% change year over year.
Hanmi Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 54.00%, a -4.93% change year over year.
Hanmi Pharm. Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 56.79%, a 6.67% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 128940.KS

Hanmi Pharm. Co., Ltd.

CEO	Mr. Jae-Hyun Park
IPO Date	July 30, 2010
Location	South Korea
Headquarters	14, Wiryeseong-daero
Employees	2,270
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.

Key trends

Past 5 years